InoPd

Phase 3

CCellCentric Ltd.

InoPd is one of 3 therapeutic programs targeting Multiple Myeloma, Refractory. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Multiple Myeloma, RefractoryRecruiting

Multiple Myeloma, RefractoryPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Multiple Myeloma, Refractory

#DrugCompanyPhaseTrials

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 2

Decadron

AAspen Global Incorporated

Phase 2

1 3

InoPd

CCellCentric Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Recruiting

Multiple Myeloma, Refractory

NCT07772024

Clinical

Trials by Indication[1]

Multiple Myeloma, Refractory1 trial

A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate Inobrodib in Combination With Pomalidomide and Dexamethasone Versus Standard Available Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·CCellCentric Ltd.·Phase 3·NCT07772024·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for InoPd. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for InoPd. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — CellCentric Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: CCellCentric Ltd.

InoPd

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Multiple Myeloma, Refractory1 trial

References

Drug Info

Quick Facts

Related News